Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — Results from a systematic review and meta-analysis of randomized controlled trials

Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein (CRP) plasma levels and other cardiovascular (CV) risk factors is inconclusive. Therefore, we performed a meta-analysis to evaluate the effica...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	International journal of cardiology Ročník 189; s. 47 - 55
Hlavní autoři:	Sahebkar, Amirhossein, Serban, Corina, Ursoniu, Sorin, Wong, Nathan D., Muntner, Paul, Graham, Ian M., Mikhailidis, Dimitri P., Rizzo, Manfredi, Rysz, Jacek, Sperling, Laurence S., Lip, Gregory Y.H., Banach, Maciej
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands Elsevier B.V 15.06.2015
Témata:	Antioxidants Antioxidants - administration & dosage C reactive protein C-Reactive Protein - drug effects C-Reactive Protein - metabolism Cardiotonic Agents Cardiovascular Cardiovascular Diseases - drug therapy Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control CRP Female Humans Inflammation Male Prognosis Randomized Controlled Trials as Topic Resveratrol Risk Assessment Severity of Illness Index Stilbenes - administration & dosage Survival Rate Treatment Outcome CRP Antioxidants Inflammation C reactive protein Resveratrol
ISSN:	0167-5273, 1874-1754, 1874-1754
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein (CRP) plasma levels and other cardiovascular (CV) risk factors is inconclusive. Therefore, we performed a meta-analysis to evaluate the efficacy of resveratrol supplementation on plasma CRP concentrations and selected predictors of CV risk. The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE (up to August 31, 2014) to identify RCTs investigating the effects of resveratrol supplementation on selected CV risk factors. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence intervals (CI) as summary statistics. Meta-analysis of data from 10 RCTs (11 treatment arms) did not support a significant effect of resveratrol supplementation in altering plasma CRP concentrations (WMD: −0.144mg/L, 95% CI: −0.968–0.680, p=0.731). Resveratrol supplementation was not found to alter plasma levels of total cholesterol (WMD: 1.49mg/dL, 95% CI: −14.96–17.93, p=0.859), low density lipoprotein cholesterol (WMD: −0.31mg/dL, 95% CI: −9.57–8.95, p=0.948), triglycerides (WMD: 2.67mg/dL, 95% CI: −28.34–33.67, p=0.866), and glucose (WMD: 1.28mg/dL, 95% CI: −5.28–7.84, p=0.703). It also slightly reduced high density lipoprotein cholesterol concentrations (WMD: −4.18mg/dL, 95% CI: −6.54 to −1.82, p=0.001). Likewise, no significant effect was observed on systolic (WMD: 0.82mmHg, 95% CI: −8.86–10.50, p=0.868) and diastolic blood pressure (WMD: 1.72mmHg, 95% CI: −6.29–9.73, p=0.674). This meta-analysis of available RCTs does not suggest any benefit of resveratrol supplementation on CV risk factors. Larger, well-designed trials are necessary to confirm these results.
AbstractList	Abstract Introduction Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein (CRP) plasma levels and other cardiovascular (CV) risk factors is inconclusive. Therefore, we performed a meta-analysis to evaluate the efficacy of resveratrol supplementation on plasma CRP concentrations and selected predictors of CV risk. Methods The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE (up to August 31, 2014) to identify RCTs investigating the effects of resveratrol supplementation on selected CV risk factors. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence intervals (CI) as summary statistics. Results Meta-analysis of data from 10 RCTs (11 treatment arms) did not support a significant effect of resveratrol supplementation in altering plasma CRP concentrations (WMD: − 0.144 mg/L, 95% CI: − 0.968–0.680, p = 0.731). Resveratrol supplementation was not found to alter plasma levels of total cholesterol (WMD: 1.49 mg/dL, 95% CI: − 14.96–17.93, p = 0.859), low density lipoprotein cholesterol (WMD: − 0.31 mg/dL, 95% CI: − 9.57–8.95, p = 0.948), triglycerides (WMD: 2.67 mg/dL, 95% CI: − 28.34–33.67, p = 0.866), and glucose (WMD: 1.28 mg/dL, 95% CI: − 5.28–7.84, p = 0.703). It also slightly reduced high density lipoprotein cholesterol concentrations (WMD: − 4.18 mg/dL, 95% CI: − 6.54 to − 1.82, p = 0.001). Likewise, no significant effect was observed on systolic (WMD: 0.82 mm Hg, 95% CI: − 8.86–10.50, p = 0.868) and diastolic blood pressure (WMD: 1.72 mm Hg, 95% CI: − 6.29–9.73, p = 0.674). Conclusions This meta-analysis of available RCTs does not suggest any benefit of resveratrol supplementation on CV risk factors. Larger, well-designed trials are necessary to confirm these results. Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein (CRP) plasma levels and other cardiovascular (CV) risk factors is inconclusive. Therefore, we performed a meta-analysis to evaluate the efficacy of resveratrol supplementation on plasma CRP concentrations and selected predictors of CV risk.INTRODUCTIONNumerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein (CRP) plasma levels and other cardiovascular (CV) risk factors is inconclusive. Therefore, we performed a meta-analysis to evaluate the efficacy of resveratrol supplementation on plasma CRP concentrations and selected predictors of CV risk.The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE (up to August 31, 2014) to identify RCTs investigating the effects of resveratrol supplementation on selected CV risk factors. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence intervals (CI) as summary statistics.METHODSThe search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE (up to August 31, 2014) to identify RCTs investigating the effects of resveratrol supplementation on selected CV risk factors. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence intervals (CI) as summary statistics.Meta-analysis of data from 10 RCTs (11 treatment arms) did not support a significant effect of resveratrol supplementation in altering plasma CRP concentrations (WMD: -0.144 mg/L, 95% CI: -0.968-0.680, p = 0.731). Resveratrol supplementation was not found to alter plasma levels of total cholesterol (WMD: 1.49 mg/dL, 95% CI: -14.96-17.93, p = 0.859), low density lipoprotein cholesterol (WMD: -0.31 mg/dL, 95% CI: -9.57-8.95, p = 0.948), triglycerides (WMD: 2.67 mg/dL, 95% CI: -28.34-33.67, p = 0.866), and glucose (WMD: 1.28 mg/dL, 95% CI: -5.28-7.84, p = 0.703). It also slightly reduced high density lipoprotein cholesterol concentrations (WMD: -4.18 mg/dL, 95% CI: -6.54 to -1.82, p = 0.001). Likewise, no significant effect was observed on systolic (WMD: 0.82 mmHg, 95% CI: -8.86-10.50, p = 0.868) and diastolic blood pressure (WMD: 1.72 mm Hg, 95% CI: -6.29-9.73, p=0.674).RESULTSMeta-analysis of data from 10 RCTs (11 treatment arms) did not support a significant effect of resveratrol supplementation in altering plasma CRP concentrations (WMD: -0.144 mg/L, 95% CI: -0.968-0.680, p = 0.731). Resveratrol supplementation was not found to alter plasma levels of total cholesterol (WMD: 1.49 mg/dL, 95% CI: -14.96-17.93, p = 0.859), low density lipoprotein cholesterol (WMD: -0.31 mg/dL, 95% CI: -9.57-8.95, p = 0.948), triglycerides (WMD: 2.67 mg/dL, 95% CI: -28.34-33.67, p = 0.866), and glucose (WMD: 1.28 mg/dL, 95% CI: -5.28-7.84, p = 0.703). It also slightly reduced high density lipoprotein cholesterol concentrations (WMD: -4.18 mg/dL, 95% CI: -6.54 to -1.82, p = 0.001). Likewise, no significant effect was observed on systolic (WMD: 0.82 mmHg, 95% CI: -8.86-10.50, p = 0.868) and diastolic blood pressure (WMD: 1.72 mm Hg, 95% CI: -6.29-9.73, p=0.674).This meta-analysis of available RCTs does not suggest any benefit of resveratrol supplementation on CV risk factors. Larger, well-designed trials are necessary to confirm these results.CONCLUSIONSThis meta-analysis of available RCTs does not suggest any benefit of resveratrol supplementation on CV risk factors. Larger, well-designed trials are necessary to confirm these results. Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein (CRP) plasma levels and other cardiovascular (CV) risk factors is inconclusive. Therefore, we performed a meta-analysis to evaluate the efficacy of resveratrol supplementation on plasma CRP concentrations and selected predictors of CV risk. The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE (up to August 31, 2014) to identify RCTs investigating the effects of resveratrol supplementation on selected CV risk factors. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence intervals (CI) as summary statistics. Meta-analysis of data from 10 RCTs (11 treatment arms) did not support a significant effect of resveratrol supplementation in altering plasma CRP concentrations (WMD: -0.144 mg/L, 95% CI: -0.968-0.680, p = 0.731). Resveratrol supplementation was not found to alter plasma levels of total cholesterol (WMD: 1.49 mg/dL, 95% CI: -14.96-17.93, p = 0.859), low density lipoprotein cholesterol (WMD: -0.31 mg/dL, 95% CI: -9.57-8.95, p = 0.948), triglycerides (WMD: 2.67 mg/dL, 95% CI: -28.34-33.67, p = 0.866), and glucose (WMD: 1.28 mg/dL, 95% CI: -5.28-7.84, p = 0.703). It also slightly reduced high density lipoprotein cholesterol concentrations (WMD: -4.18 mg/dL, 95% CI: -6.54 to -1.82, p = 0.001). Likewise, no significant effect was observed on systolic (WMD: 0.82 mmHg, 95% CI: -8.86-10.50, p = 0.868) and diastolic blood pressure (WMD: 1.72 mm Hg, 95% CI: -6.29-9.73, p=0.674). This meta-analysis of available RCTs does not suggest any benefit of resveratrol supplementation on CV risk factors. Larger, well-designed trials are necessary to confirm these results. Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein (CRP) plasma levels and other cardiovascular (CV) risk factors is inconclusive. Therefore, we performed a meta-analysis to evaluate the efficacy of resveratrol supplementation on plasma CRP concentrations and selected predictors of CV risk. The search included PUBMED, Cochrane Library, Web of Science, Scopus, and EMBASE (up to August 31, 2014) to identify RCTs investigating the effects of resveratrol supplementation on selected CV risk factors. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence intervals (CI) as summary statistics. Meta-analysis of data from 10 RCTs (11 treatment arms) did not support a significant effect of resveratrol supplementation in altering plasma CRP concentrations (WMD: −0.144mg/L, 95% CI: −0.968–0.680, p=0.731). Resveratrol supplementation was not found to alter plasma levels of total cholesterol (WMD: 1.49mg/dL, 95% CI: −14.96–17.93, p=0.859), low density lipoprotein cholesterol (WMD: −0.31mg/dL, 95% CI: −9.57–8.95, p=0.948), triglycerides (WMD: 2.67mg/dL, 95% CI: −28.34–33.67, p=0.866), and glucose (WMD: 1.28mg/dL, 95% CI: −5.28–7.84, p=0.703). It also slightly reduced high density lipoprotein cholesterol concentrations (WMD: −4.18mg/dL, 95% CI: −6.54 to −1.82, p=0.001). Likewise, no significant effect was observed on systolic (WMD: 0.82mmHg, 95% CI: −8.86–10.50, p=0.868) and diastolic blood pressure (WMD: 1.72mmHg, 95% CI: −6.29–9.73, p=0.674). This meta-analysis of available RCTs does not suggest any benefit of resveratrol supplementation on CV risk factors. Larger, well-designed trials are necessary to confirm these results.
Author	Muntner, Paul Rysz, Jacek Banach, Maciej Lip, Gregory Y.H. Ursoniu, Sorin Serban, Corina Sperling, Laurence S. Sahebkar, Amirhossein Graham, Ian M. Wong, Nathan D. Mikhailidis, Dimitri P. Rizzo, Manfredi
Author_xml	– sequence: 1 givenname: Amirhossein surname: Sahebkar fullname: Sahebkar, Amirhossein organization: Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran – sequence: 2 givenname: Corina surname: Serban fullname: Serban, Corina organization: Department of Functional Sciences, Discipline of Pathophysiology, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania – sequence: 3 givenname: Sorin surname: Ursoniu fullname: Ursoniu, Sorin organization: Department of Functional Sciences, Discipline of Public Health, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania – sequence: 4 givenname: Nathan D. surname: Wong fullname: Wong, Nathan D. organization: Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, CA, USA – sequence: 5 givenname: Paul surname: Muntner fullname: Muntner, Paul organization: Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA – sequence: 6 givenname: Ian M. surname: Graham fullname: Graham, Ian M. organization: Department of Epidemiology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands – sequence: 7 givenname: Dimitri P. surname: Mikhailidis fullname: Mikhailidis, Dimitri P. organization: Department of Clinical Biochemistry, Royal Free Campus, University College London Medical School, University College London (UCL), London, UK – sequence: 8 givenname: Manfredi surname: Rizzo fullname: Rizzo, Manfredi organization: Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Italy – sequence: 9 givenname: Jacek surname: Rysz fullname: Rysz, Jacek organization: Chair of Nephrology and Hypertension, Medical University of Lodz, Poland – sequence: 10 givenname: Laurence S. surname: Sperling fullname: Sperling, Laurence S. organization: Department of Medicine and Division of Cardiology, Emory University, Atlanta, GA, USA – sequence: 11 givenname: Gregory Y.H. surname: Lip fullname: Lip, Gregory Y.H. organization: University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK – sequence: 12 givenname: Maciej orcidid: 0000-0001-6690-6874 surname: Banach fullname: Banach, Maciej email: maciejbanach@aol.co.uk organization: Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25885871$$D View this record in MEDLINE/PubMed
BookMark	eNqFUsuKFDEUDTLi9Iz-gUiWbqpNKkklLSIMjS9oEHysQzp1A-lOVcYk1dKu_Ah_xR_yS0xNjy4EdZVLOOfce8-5F-hsjCMg9JCSJSW0e7Jb-p01qV-2hIol4UtC1B20oEryhkrBz9CiwmQjWsnO0UXOO0IIX63UPXTeCqWEknSBvm-M3ePoMDjnrbHHuU6QD5BMSTHgOOJ1k8DY4g-Ar1Ms4Edsxh5nCGAL9HiewseDyXYKJuHk8x67Sogp4x9fv-F3kKdQMnYpDtjgfMwFBlO8rY0OHj7fqA1QTGNGE47Z55sh6m8c_Je5QRznWUItS_Im5PvorqsPPLh9L9HHly8-rF83m7ev3qyvNo3lipaGMe6k6pSQwnWO8LZ3olNb7ljbtbYHurIr1m6pNIYJJixlW9ltAQwwuTLOskv0-KRb9_40QS568NlCCGaEOGVNO8WE5JLRCn10C522A_T6OvnBpKP-ZXUF8BPApphzAvcbQomeE9U7fUpUz4lqwnVNtNKe_kGzvlTzZkuMD_8jPz-RoZpUrU7aBj_WnMMejpB3cUrV8bqHzq0m-v18MPO9UEGIpIpXgWd_F9B99P_u_xPAHtef
CitedBy_id	crossref_primary_10_3389_fnut_2021_717343 crossref_primary_10_1177_1535370216647181 crossref_primary_10_1038_s41598_018_36204_7 crossref_primary_10_3389_fpsyt_2016_00159 crossref_primary_10_1016_j_bcp_2017_04_033 crossref_primary_10_1016_j_ibror_2020_06_004 crossref_primary_10_1016_j_hermed_2017_09_002 crossref_primary_10_1155_2021_3619510 crossref_primary_10_1007_s00592_017_1097_4 crossref_primary_10_1039_C8FO01259H crossref_primary_10_3390_nu11102381 crossref_primary_10_1016_j_livres_2025_04_002 crossref_primary_10_1016_j_arr_2024_102532 crossref_primary_10_1155_2020_6381380 crossref_primary_10_3390_nu16132131 crossref_primary_10_1007_s10522_021_09913_2 crossref_primary_10_1016_j_nut_2016_04_007 crossref_primary_10_1016_j_ctim_2022_102863 crossref_primary_10_1016_j_numecd_2019_11_015 crossref_primary_10_1016_j_clinthera_2018_05_015 crossref_primary_10_3390_nu9060596 crossref_primary_10_3390_nu15132949 crossref_primary_10_2174_0109298673255218231005062112 crossref_primary_10_1093_ajcn_nqab250 crossref_primary_10_1002_ptr_70025 crossref_primary_10_1080_10408398_2021_1875189 crossref_primary_10_1097_MNH_0000000000000198 crossref_primary_10_2174_1381612826666201207230956 crossref_primary_10_1016_j_arr_2018_05_004 crossref_primary_10_2174_0929867330666230607125432 crossref_primary_10_3390_nu8020073 crossref_primary_10_1002_biof_2115 crossref_primary_10_1002_jcsm_13057 crossref_primary_10_2174_0929867330666230504121523 crossref_primary_10_2174_0929867331666230724124013 crossref_primary_10_3390_molecules26113081 crossref_primary_10_1016_j_biotechadv_2018_08_003 crossref_primary_10_1016_j_canlet_2019_06_001 crossref_primary_10_1080_09637486_2017_1391752 crossref_primary_10_3389_fphys_2021_733696 crossref_primary_10_2174_0115748871303052240529102003 crossref_primary_10_1007_s12035_024_04030_w crossref_primary_10_3390_diseases13070221 crossref_primary_10_1016_j_clnu_2022_11_009 crossref_primary_10_1016_j_toxicon_2025_108433 crossref_primary_10_3389_fphys_2022_795980 crossref_primary_10_1016_j_cdnut_2024_103785 crossref_primary_10_1016_j_foodres_2019_108749 crossref_primary_10_1002_ptr_7262 crossref_primary_10_1016_j_arr_2016_08_004 crossref_primary_10_1007_s43440_024_00585_6 crossref_primary_10_1016_j_ctim_2019_102251 crossref_primary_10_1016_j_jddst_2025_106908 crossref_primary_10_1111_bph_13779 crossref_primary_10_1016_j_jff_2022_105360 crossref_primary_10_1007_s40292_019_00309_5 crossref_primary_10_1002_biof_1960 crossref_primary_10_1155_2021_4136071 crossref_primary_10_1161_JAHA_123_033748 crossref_primary_10_3390_ijms21228706 crossref_primary_10_1007_s00394_024_03335_9 crossref_primary_10_1093_advances_nmaa148 crossref_primary_10_1155_2021_4041415 crossref_primary_10_1016_j_phymed_2015_10_018 crossref_primary_10_1007_s40292_019_00324_6 crossref_primary_10_1002_open_202200098 crossref_primary_10_1093_nutrit_nuae025 crossref_primary_10_3389_fimmu_2018_02992 crossref_primary_10_1186_s12944_020_1198_x crossref_primary_10_1016_j_prostaglandins_2024_106903 crossref_primary_10_1016_j_fitote_2025_106800 crossref_primary_10_1016_j_nutres_2018_03_015 crossref_primary_10_3389_fimmu_2019_00837 crossref_primary_10_1002_biof_1958 crossref_primary_10_1007_s11886_018_0994_7 crossref_primary_10_1016_j_ejphar_2021_174380 crossref_primary_10_1016_j_jacc_2019_11_062 crossref_primary_10_1016_j_exger_2017_06_015 crossref_primary_10_1038_s41430_018_0253_4 crossref_primary_10_1016_j_nut_2015_11_013 crossref_primary_10_1016_j_cdnut_2023_102059 crossref_primary_10_1016_j_canlet_2024_216955 crossref_primary_10_1016_j_atherosclerosis_2017_08_027 crossref_primary_10_1016_j_jff_2022_105192 crossref_primary_10_1089_met_2016_0035 crossref_primary_10_1016_j_mrrev_2025_108550 crossref_primary_10_3390_nu10111651 crossref_primary_10_1016_j_tice_2025_102911 crossref_primary_10_1002_ptr_7763 crossref_primary_10_1080_10408398_2017_1349076 crossref_primary_10_1016_j_bbamem_2023_184212 crossref_primary_10_1039_C8FO01997E crossref_primary_10_1038_s41440_023_01231_z crossref_primary_10_1007_s43440_025_00694_w crossref_primary_10_3390_antiox11071273 crossref_primary_10_1016_j_jddst_2023_105315 crossref_primary_10_1016_j_jneuroim_2021_577758 crossref_primary_10_1093_nutrit_nux047 crossref_primary_10_1007_s00210_025_04314_5 crossref_primary_10_3390_ijms20071523 crossref_primary_10_1016_j_biopha_2022_113274 crossref_primary_10_3389_fphar_2021_747625 crossref_primary_10_1016_j_jconrel_2017_11_024 crossref_primary_10_1007_s10787_021_00902_y crossref_primary_10_1016_j_sajb_2025_08_017 crossref_primary_10_1016_j_freeradbiomed_2016_03_037 crossref_primary_10_1002_med_22064 crossref_primary_10_1002_ptr_7194 crossref_primary_10_3389_fphys_2016_00448 crossref_primary_10_1016_j_phrs_2021_105725 crossref_primary_10_1016_j_drudis_2023_103599 crossref_primary_10_1111_bph_13743 crossref_primary_10_3390_metabo10110428 crossref_primary_10_3390_ijms23074027 crossref_primary_10_1016_j_phrs_2017_12_029 crossref_primary_10_1007_s00210_024_03527_4 crossref_primary_10_1080_10408398_2017_1422480 crossref_primary_10_1155_2020_2647807 crossref_primary_10_1186_s12986_018_0274_y crossref_primary_10_1002_cre2_673 crossref_primary_10_3109_07853890_2015_1078905 crossref_primary_10_1080_1061186X_2020_1870987 crossref_primary_10_1007_s11883_024_01197_4 crossref_primary_10_1007_s11845_020_02441_x crossref_primary_10_1016_j_jep_2021_114407 crossref_primary_10_1089_ars_2018_7545 crossref_primary_10_1007_s11357_020_00295_w crossref_primary_10_3390_molecules26113168 crossref_primary_10_3390_ijms221810152 crossref_primary_10_1002_ptr_7069 crossref_primary_10_3390_nu16234076 crossref_primary_10_1002_jcp_27950 crossref_primary_10_1002_ptr_6655 crossref_primary_10_3390_jcm11175251 crossref_primary_10_1002_ptr_6419
Cites_doi	10.1523/JNEUROSCI.0385-14.2014 10.1038/444566a 10.1016/j.cmet.2012.09.015 10.3109/10717544.2014.924167 10.2337/db12-0975 10.2174/1381612811319300007 10.1016/j.clnu.2014.03.009 10.1016/j.foodchem.2014.06.082 10.1016/j.nutres.2011.09.028 10.1089/met.2014.1505 10.1166/jbn.2014.1897 10.1124/dmd.104.000885 10.1002/mnfr.200500010 10.1016/j.phrs.2009.01.009 10.1038/nrd2060 10.1093/nar/gku1033 10.1016/S0076-6879(01)35239-4 10.3390/ijms150914949 10.1002/mnfr.200900437 10.1016/j.bcp.2013.02.015 10.3748/wjg.v20.i23.7366 10.1016/j.amjhyper.2004.12.012 10.1111/j.2042-7158.2010.01197.x 10.2174/187152807781696464 10.1227/01.neu.0000450234.14363.07 10.1111/j.0006-341X.2000.00455.x 10.1016/S0009-9120(02)00397-1 10.1096/fj.03-0168rev 10.1016/j.pharep.2014.04.006 10.1002/mnfr.201200589 10.1161/HYPERTENSIONAHA.109.133397 10.1016/j.phrs.2015.03.009 10.1016/S0006-2952(99)00380-9 10.1021/jf034150f 10.1016/j.foodchem.2009.11.032 10.1210/jc.2010-0482 10.1038/hr.2009.47 10.2174/1871520614666140521121722 10.1016/j.nut.2012.07.006 10.1021/jf0112973 10.1042/BJ20091857 10.1155/2014/816307 10.3945/ajcn.2009.28822 10.1111/j.1440-1681.2007.04667.x 10.4161/auto.27593 10.1152/japplphysiol.00881.2006 10.1136/bmj.b2535 10.3233/CH-2011-1424 10.1111/j.1749-6632.2010.05842.x 10.1016/j.jada.2011.05.015 10.1016/j.amjcard.2012.03.030 10.1016/j.nut.2013.11.016 10.1089/dna.2012.1947 10.1210/jc.2010-1812 10.1530/ERC-13-0171 10.1080/004982500406435 10.1016/0140-6736(92)91277-F 10.1111/bph.12409 10.1002/mnfr.201100117 10.1016/j.lfs.2013.12.011 10.1016/j.atherosclerosis.2008.11.011 10.3945/ajcn.113.082024 10.1016/j.jchromb.2006.10.017
ContentType	Journal Article
Copyright	2015 Elsevier Ireland Ltd Elsevier Ireland Ltd Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Copyright_xml	– notice: 2015 Elsevier Ireland Ltd – notice: Elsevier Ireland Ltd – notice: Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
CorporateAuthor	Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group Lipid and Blood Pressure Meta-analysis Collaboration Group
CorporateAuthor_xml	– name: Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group – name: Lipid and Blood Pressure Meta-analysis Collaboration Group
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.ijcard.2015.04.008
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1874-1754
EndPage	55
ExternalDocumentID	25885871 10_1016_j_ijcard_2015_04_008 1_s2_0_S0167527315007184 S0167527315007184
Genre	Meta-Analysis Systematic Review Journal Article
GroupedDBID	--- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ACDAQ ACGFS ACIEU ACIUM ACLOT ACRLP ACVFH ADBBV ADCNI ADEZE AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AXJTR BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KOM M29 M41 MO0 N9A O-L O9- OA. OAUVE OL~ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SAE SCC SDF SDG SEL SES SPCBC SSH SSZ T5K UV1 Z5R ~G- ~HD .55 .GJ 0SF 29J AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFFNX AFJKZ AFKWA AHHHB AJOXV AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HEB HMK HMO HVGLF HZ~ NCXOZ R2- RIG SEW WUQ X7M ZGI 9DU AAYXX AGQPQ AIGII APXCP CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c481t-334f7868575f6f042df568b4f3262cde19c932b17aa3535c13b76beeae379afc3
ISICitedReferencesCount	153
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000355108300009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0167-5273 1874-1754
IngestDate	Sun Sep 28 05:52:50 EDT 2025 Sun Jul 13 01:33:39 EDT 2025 Sat Nov 29 05:34:39 EST 2025 Tue Nov 18 19:37:02 EST 2025 Sun Feb 23 10:19:03 EST 2025 Tue Oct 14 19:31:34 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Keywords	CRP Antioxidants Inflammation C reactive protein Resveratrol
Language	English
License	Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c481t-334f7868575f6f042df568b4f3262cde19c932b17aa3535c13b76beeae379afc3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4
ORCID	0000-0001-6690-6874
PMID	25885871
PQID	1683574731
PQPubID	23479
PageCount	9
ParticipantIDs	proquest_miscellaneous_1683574731 pubmed_primary_25885871 crossref_primary_10_1016_j_ijcard_2015_04_008 crossref_citationtrail_10_1016_j_ijcard_2015_04_008 elsevier_clinicalkeyesjournals_1_s2_0_S0167527315007184 elsevier_clinicalkey_doi_10_1016_j_ijcard_2015_04_008
PublicationCentury	2000
PublicationDate	2015-06-15
PublicationDateYYYYMMDD	2015-06-15
PublicationDate_xml	– month: 06 year: 2015 text: 2015-06-15 day: 15
PublicationDecade	2010
PublicationPlace	Netherlands
PublicationPlace_xml	– name: Netherlands
PublicationTitle	International journal of cardiology
PublicationTitleAlternate	Int J Cardiol
PublicationYear	2015
Publisher	Elsevier B.V
Publisher_xml	– name: Elsevier B.V
References	Borriello, Bencivenga, Caldarelli, Tramontano, Borgia, Pirozzi (bb0090) 2013; 19 Boocock, Patel, Faust, Normolle, Marczylo, Crowell (bb0260) 2007; 848 Cottart, Nivet-Antoine, Laguillier-Morizot, Beaudeux (bb0290) 2010; 54 Renaud, de Lorgeril (bb0020) 1992; 339 Liu, Ma, Zhang, He, Huang (bb0225) 2015; 34 Kang, Jang, Chae, Oh, Choi, Lee (bb0120) 2009; 59 Chow, Hshu, Wang, Chen (bb0115) 2007; 102 Raj, Louis, Thandapilly, Movahed, Zieroth, Netticadan (bb0050) 2014; 95 Poulsen, Vestergaard, Clasen, Radko, Christensen, Stødkilde-Jørgensen (bb0185) 2013; 62 De Santi, Pietrabissa, Spisni, Mosca, Pacifici (bb0310) 2000; 30 Zarzuelo, Lopez-Sepulveda, Sanchez, Romero, Gomez-Guzman, Ungvary (bb0110) 2013; 85 Ciddi, Dodda (bb0065) 2014; 66 Carter, D'Orazio, Pearson (bb0085) 2014; 21 Johnson, Nihal, Siddiqui, Scarlett, Bailey, Mukhtar (bb0315) 2011; 55 Wenzel, Somoza (bb0270) 2005; 49 Lyons, Yu, Toma, Cho, Reiboldt, Lee (bb0015) 2003; 51 Militaru, Donoiu, Craciun, Scorei, Bulearca, Scorei (bb0180) 2013; 29 Weiner, Ducruet (bb0080) 2014; 74 Bremer (bb0075) 2014; 10 Andreadi, Britton, Patel, Brown (bb0275) 2014; 10 Robinson, Mock, Liang (bb0285) 2014; 1–6 Csiszar, Labinskyy, Olson, Pinto, Gupte, Wu (bb0240) 2009; 54 Liu, Zhou, Wang, Mi (bb0255) 2014; 99 Bashmakov, Assaad-Khalil, Abou Seif, Udumyan, Megallaa, Rohoma (bb0070) 2014; 2014 Witte, Kerti, Margulies, Flöel (bb0195) 2014; 34 Yin, Si, Xu, Dong, Zheng, Lu (bb0335) 2014; 10 Yoshino, Conte, Fontana, Mittendorfer, Imai, Schechtman (bb0205) 2012; 16 Collaboration (bb0210) 2013 Banach, Aronow, Serban, Sahabkar, Rysz, Voroneanu, Covic (bb0265) 2015 Pervaiz (bb0025) 2003; 17 Martinez, Moreno (bb0105) 2000; 59 Bakker, Van Erk, Pellis, Wopereis, Rubingh, Cnubben (bb0160) 2010; 91 Goldberg, Yan, Soleas (bb0040) 2003; 36 Zu, Zhang, Wang, Zhao, Han, Wang (bb0330) 2014 Aguirre, Portillo, Hijona, Bujanda (bb0055) 2014; 20 Das, Das (bb0100) 2007; 6 Baczko, Liknes, Yang, Hamming, Searle, Jaeger (bb0045) 2014; 171 Corder, Mullen, Khan, Marks, Wood, Carrier (bb0295) 2006; 444 Yang, Li, Ren (bb0095) 2014; 14 Borenstein, Higgins (bb0145) 2005 Wang, Huang, Zou, Su, Shan, Yang (bb0130) 2007; 34 Feringa, Laskey, Dickson, Coleman (bb0250) 2011; 111 Baur, Sinclair (bb0005) 2006; 5 Walle, Hsieh, DeLegge, Oatis, Walle (bb0030) 2004; 32 Walle (bb0305) 2011; 1215 Ghanim, Sia, Abuaysheh, Korzeniewski, Patnaik, Marumganti (bb0215) 2010; 95 Toklu, Sehirli, Ersahin, Suleymanoglu, Yiginer, Emekli-Alturfan (bb0245) 2010; 62 Moher, Liberati, Tetzlaff, Altman, Group (bb0140) 2009; 339 Sahebkar (bb0150) 2013; 32 Wang, Martins-Green (bb0200) 2014; 15 Brito, Devillard, Negre-Salvayre, Almeida, Dinis, Salvayre (bb0125) 2009; 205 Davidov-Pardo, McClements (bb0325) 2015; 167 Calamini, Ratia, Malkowski, Cuendet, Pezzuto, Santarsiero (bb0280) 2010; 429 Ghanim, Sia, Korzeniewski, Lohano, Abuaysheh, Marumganti (bb0220) 2011; 96 Duval, Tweedie (bb0155) 2000; 56 Burns, Yokota, Ashihara, Lean, Crozier (bb0010) 2002; 50 Ortuño, Covas, Farre, Pujadas, Fito, Khymenets (bb0320) 2010; 120 Soleas, Angelini, Grass, Diamandis, Goldberg (bb0035) 2001; 335 Andrade, Paraiso, de Oliveira, Martins, Neto, Guimaraes (bb0060) 2014; 30 Tomé-Carneiro, Gonzálvez, Larrosa, Yáñez-Gascón, García-Almagro, Ruiz-Ros (bb0190) 2012; 110 Inanaga, Ichiki, Matsuura, Miyazaki, Hashimoto, Takeda (bb0230) 2009; 32 Fujitaka, Otani, Jo, Jo, Nomura, Iwasaki (bb0170) 2011; 31 Miatello, Vazquez, Renna, Cruzado, Zumino, Risler (bb0235) 2005; 18 Cottart, Nivet-Antoine, Beaudeux (bb0300) 2014; 58 Magyar, Halmosi, Palfi, Feher, Czopf, Fulop (bb0175) 2012; 50 Bollmann, Art, Henke, Schrick, Besche, Bros (bb0135) 2014; 42 Bashmakov, Assaad-Khalil, Abou Seif, Udumyan, Megallaa, Rohoma (bb0165) 2014; 2014 Yang (10.1016/j.ijcard.2015.04.008_bb0095) 2014; 14 Ciddi (10.1016/j.ijcard.2015.04.008_bb0065) 2014; 66 Zarzuelo (10.1016/j.ijcard.2015.04.008_bb0110) 2013; 85 Inanaga (10.1016/j.ijcard.2015.04.008_bb0230) 2009; 32 Calamini (10.1016/j.ijcard.2015.04.008_bb0280) 2010; 429 Magyar (10.1016/j.ijcard.2015.04.008_bb0175) 2012; 50 Chow (10.1016/j.ijcard.2015.04.008_bb0115) 2007; 102 Walle (10.1016/j.ijcard.2015.04.008_bb0305) 2011; 1215 Feringa (10.1016/j.ijcard.2015.04.008_bb0250) 2011; 111 Andreadi (10.1016/j.ijcard.2015.04.008_bb0275) 2014; 10 Martinez (10.1016/j.ijcard.2015.04.008_bb0105) 2000; 59 Johnson (10.1016/j.ijcard.2015.04.008_bb0315) 2011; 55 Fujitaka (10.1016/j.ijcard.2015.04.008_bb0170) 2011; 31 Cottart (10.1016/j.ijcard.2015.04.008_bb0300) 2014; 58 Csiszar (10.1016/j.ijcard.2015.04.008_bb0240) 2009; 54 Goldberg (10.1016/j.ijcard.2015.04.008_bb0040) 2003; 36 Andrade (10.1016/j.ijcard.2015.04.008_bb0060) 2014; 30 Raj (10.1016/j.ijcard.2015.04.008_bb0050) 2014; 95 Borriello (10.1016/j.ijcard.2015.04.008_bb0090) 2013; 19 Brito (10.1016/j.ijcard.2015.04.008_bb0125) 2009; 205 Collaboration (10.1016/j.ijcard.2015.04.008_bb0210) Witte (10.1016/j.ijcard.2015.04.008_bb0195) 2014; 34 Bashmakov (10.1016/j.ijcard.2015.04.008_bb0165) 2014; 2014 Ghanim (10.1016/j.ijcard.2015.04.008_bb0215) 2010; 95 Bakker (10.1016/j.ijcard.2015.04.008_bb0160) 2010; 91 Tomé-Carneiro (10.1016/j.ijcard.2015.04.008_bb0190) 2012; 110 Pervaiz (10.1016/j.ijcard.2015.04.008_bb0025) 2003; 17 Wang (10.1016/j.ijcard.2015.04.008_bb0130) 2007; 34 Toklu (10.1016/j.ijcard.2015.04.008_bb0245) 2010; 62 Das (10.1016/j.ijcard.2015.04.008_bb0100) 2007; 6 Borenstein (10.1016/j.ijcard.2015.04.008_bb0145) 2005 Robinson (10.1016/j.ijcard.2015.04.008_bb0285) 2014; 1–6 Yin (10.1016/j.ijcard.2015.04.008_bb0335) 2014; 10 De Santi (10.1016/j.ijcard.2015.04.008_bb0310) 2000; 30 Ortuño (10.1016/j.ijcard.2015.04.008_bb0320) 2010; 120 Baur (10.1016/j.ijcard.2015.04.008_bb0005) 2006; 5 Walle (10.1016/j.ijcard.2015.04.008_bb0030) 2004; 32 Cottart (10.1016/j.ijcard.2015.04.008_bb0290) 2010; 54 Militaru (10.1016/j.ijcard.2015.04.008_bb0180) 2013; 29 Wenzel (10.1016/j.ijcard.2015.04.008_bb0270) 2005; 49 Bremer (10.1016/j.ijcard.2015.04.008_bb0075) 2014; 10 Boocock (10.1016/j.ijcard.2015.04.008_bb0260) 2007; 848 Lyons (10.1016/j.ijcard.2015.04.008_bb0015) 2003; 51 Liu (10.1016/j.ijcard.2015.04.008_bb0255) 2014; 99 Baczko (10.1016/j.ijcard.2015.04.008_bb0045) 2014; 171 Sahebkar (10.1016/j.ijcard.2015.04.008_bb0150) 2013; 32 Burns (10.1016/j.ijcard.2015.04.008_bb0010) 2002; 50 Renaud (10.1016/j.ijcard.2015.04.008_bb0020) 1992; 339 Aguirre (10.1016/j.ijcard.2015.04.008_bb0055) 2014; 20 Carter (10.1016/j.ijcard.2015.04.008_bb0085) 2014; 21 Moher (10.1016/j.ijcard.2015.04.008_bb0140) 2009; 339 Banach (10.1016/j.ijcard.2015.04.008_bb0265) 2015 Davidov-Pardo (10.1016/j.ijcard.2015.04.008_bb0325) 2015; 167 Wang (10.1016/j.ijcard.2015.04.008_bb0200) 2014; 15 Liu (10.1016/j.ijcard.2015.04.008_bb0225) 2015; 34 Kang (10.1016/j.ijcard.2015.04.008_bb0120) 2009; 59 Miatello (10.1016/j.ijcard.2015.04.008_bb0235) 2005; 18 Weiner (10.1016/j.ijcard.2015.04.008_bb0080) 2014; 74 Duval (10.1016/j.ijcard.2015.04.008_bb0155) 2000; 56 Bollmann (10.1016/j.ijcard.2015.04.008_bb0135) 2014; 42 Corder (10.1016/j.ijcard.2015.04.008_bb0295) 2006; 444 Zu (10.1016/j.ijcard.2015.04.008_bb0330) 2014 Poulsen (10.1016/j.ijcard.2015.04.008_bb0185) 2013; 62 Ghanim (10.1016/j.ijcard.2015.04.008_bb0220) 2011; 96 Soleas (10.1016/j.ijcard.2015.04.008_bb0035) 2001; 335 Yoshino (10.1016/j.ijcard.2015.04.008_bb0205) 2012; 16 Bashmakov (10.1016/j.ijcard.2015.04.008_bb0070) 2014; 2014
References_xml	– volume: 42 start-page: 12555 year: 2014 end-page: 12569 ident: bb0135 article-title: Resveratrol post-transcriptionally regulates pro-inflammatory gene expression via regulation of KSRP RNA binding activity publication-title: Nucleic Acids Res. – volume: 2014 year: 2014 ident: bb0165 article-title: Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients publication-title: Int. Sch. Res. Not. – volume: 50 start-page: 3337 year: 2002 end-page: 3340 ident: bb0010 article-title: Plant foods and herbal sources of resveratrol publication-title: J. Agric. Food Chem. – volume: 10 start-page: 1536 year: 2014 end-page: 1544 ident: bb0335 article-title: Resveratrol-loaded nanoparticles reduce oxidative stress induced by radiation or amyloid-beta in transgenic publication-title: J. Biomed. Nanotechnol. – volume: 51 start-page: 5867 year: 2003 end-page: 5870 ident: bb0015 article-title: Resveratrol in raw and baked blueberries and bilberries publication-title: J. Agric. Food Chem. – volume: 59 start-page: 865 year: 2000 end-page: 870 ident: bb0105 article-title: Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production publication-title: Biochem. Pharmacol. – volume: 15 start-page: 14949 year: 2014 end-page: 14966 ident: bb0200 article-title: Pomegranate and its components as alternative treatment for prostate cancer publication-title: Int. J. Mol. Sci. – volume: 34 start-page: 27 year: 2015 end-page: 34 ident: bb0225 article-title: Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials publication-title: Clin. Nutr. – volume: 205 start-page: 126 year: 2009 end-page: 134 ident: bb0125 article-title: Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells publication-title: Atherosclerosis – volume: 34 start-page: 1109 year: 2007 end-page: 1115 ident: bb0130 article-title: Effects of resveratrol on number and activity of endothelial progenitor cells from human peripheral blood publication-title: Clin. Exp. Pharmacol. Physiol. – volume: 10 start-page: 493 year: 2014 end-page: 495 ident: bb0075 article-title: Resveratrol use in metabolic syndrome publication-title: Metab. Syndr. Relat. Disord. – volume: 10 start-page: 524 year: 2014 end-page: 525 ident: bb0275 article-title: Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells publication-title: Autophagy – volume: 17 start-page: 1975 year: 2003 end-page: 1985 ident: bb0025 article-title: Resveratrol: from grapevines to mammalian biology publication-title: FASEB J. – volume: 66 start-page: 799 year: 2014 end-page: 803 ident: bb0065 article-title: Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies publication-title: Pharmacol. Rep. – volume: 74 start-page: N17 year: 2014 end-page: N18 ident: bb0080 article-title: Resveratrol and pharmacological potentiation in ischemic stroke publication-title: Neurosurgery – volume: 102 start-page: 1520 year: 2007 end-page: 1527 ident: bb0115 article-title: Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages publication-title: J. Appl. Physiol. – volume: 32 start-page: 188 year: 2013 end-page: 198 ident: bb0150 article-title: Does PPARgamma2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis publication-title: DNA Cell Biol. – volume: 56 start-page: 455 year: 2000 end-page: 463 ident: bb0155 article-title: Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis publication-title: Biometrics – volume: 32 start-page: 1377 year: 2004 end-page: 1382 ident: bb0030 article-title: High absorption but very low bioavailability of oral resveratrol in humans publication-title: Drug Metab. Dispos. – volume: 335 start-page: 145 year: 2001 end-page: 154 ident: bb0035 article-title: Absorption of trans-resveratrol in rats publication-title: Methods Enzymol. – start-page: 1 year: 2014 end-page: 11 ident: bb0330 article-title: Preparation and in vitro/in vivo evaluation of resveratrol-loaded carboxymethyl chitosan nanoparticles publication-title: Drug Deliv. – volume: 36 start-page: 79 year: 2003 end-page: 87 ident: bb0040 article-title: Absorption of three wine-related polyphenols in three different matrices by healthy subjects publication-title: Clin. Biochem. – volume: 50 start-page: 179 year: 2012 end-page: 187 ident: bb0175 article-title: Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease publication-title: Clin. Hemorheol. Microcirc. – volume: 444 start-page: 566 year: 2006 ident: bb0295 article-title: Oenology: red wine procyanidins and vascular health publication-title: Nature – volume: 429 start-page: 273 year: 2010 end-page: 282 ident: bb0280 article-title: Pleiotropic mechanisms facilitated by resveratrol and its metabolites publication-title: Biochem. J. – volume: 19 start-page: 5384 year: 2013 end-page: 5393 ident: bb0090 article-title: Resveratrol and cancer treatment: is hormesis a yet unsolved matter? publication-title: Curr. Pharm. Des. – volume: 55 start-page: 1169 year: 2011 end-page: 1176 ident: bb0315 article-title: Enhancing the bioavailability of resveratrol by combining it with piperine publication-title: Mol. Nutr. Food Res. – volume: 171 start-page: 92 year: 2014 end-page: 106 ident: bb0045 article-title: Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation publication-title: Br. J. Pharmacol. – volume: 1215 start-page: 9 year: 2011 end-page: 15 ident: bb0305 article-title: Bioavailability of resveratrol publication-title: Ann. N. Y. Acad. Sci. – volume: 18 start-page: 864 year: 2005 end-page: 870 ident: bb0235 article-title: Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats publication-title: Am. J. Hypertens. – volume: 99 start-page: 1510 year: 2014 end-page: 1519 ident: bb0255 article-title: Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials publication-title: Am. J. Clin. Nutr. – year: 2005 ident: bb0145 article-title: Comprehensive Meta-analysis Version 2 – volume: 14 start-page: 806 year: 2014 end-page: 825 ident: bb0095 article-title: From French paradox to cancer treatment: anti-cancer activities and mechanisms of resveratrol publication-title: Anti Cancer Agents Med. Chem. – volume: 339 start-page: b2535 year: 2009 ident: bb0140 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: BMJ – volume: 111 start-page: 1173 year: 2011 end-page: 1181 ident: bb0250 article-title: The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials publication-title: J. Am. Diet. Assoc. – volume: 16 start-page: 658 year: 2012 end-page: 664 ident: bb0205 article-title: Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance publication-title: Cell Metab. – volume: 20 start-page: 7366 year: 2014 end-page: 7380 ident: bb0055 article-title: Effects of resveratrol and other polyphenols in hepatic steatosis publication-title: World J. Gastroenterol. – volume: 54 start-page: 668 year: 2009 end-page: 675 ident: bb0240 article-title: Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats publication-title: Hypertension – volume: 30 start-page: 915 year: 2014 end-page: 919 ident: bb0060 article-title: Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation publication-title: Nutrition – volume: 120 start-page: 1123 year: 2010 end-page: 1130 ident: bb0320 article-title: Matrix effects on the bioavailability of resveratrol in humans publication-title: Food Chem. – volume: 2014 start-page: 816307 year: 2014 ident: bb0070 article-title: Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients publication-title: ISRN Endocrinol. – volume: 30 start-page: 609 year: 2000 end-page: 617 ident: bb0310 article-title: Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum publication-title: Xenobiotica – volume: 62 start-page: 1186 year: 2013 end-page: 1195 ident: bb0185 article-title: High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition publication-title: Diabetes – year: 2015 ident: bb0265 article-title: Lipids, blood pressure and kidney update 2014 publication-title: Pharmacol. Res. – volume: 339 start-page: 1523 year: 1992 end-page: 1526 ident: bb0020 article-title: Wine, alcohol, platelets, and the French paradox for coronary heart disease publication-title: Lancet – volume: 848 start-page: 182 year: 2007 end-page: 187 ident: bb0260 article-title: Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography publication-title: J. Chromatogr. B Anal. Technol. Biomed. Life Sci. – volume: 95 start-page: E1 year: 2010 end-page: E8 ident: bb0215 article-title: An antiinflammatory and reactive oxygen species suppressive effects of an extract of publication-title: J. Clin. Endocrinol. Metab. – volume: 167 start-page: 205 year: 2015 end-page: 212 ident: bb0325 article-title: Nutraceutical delivery systems: resveratrol encapsulation in grape seed oil nanoemulsions formed by spontaneous emulsification publication-title: Food Chem. – volume: 62 start-page: 1784 year: 2010 end-page: 1793 ident: bb0245 article-title: Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats publication-title: J. Pharm. Pharmacol. – volume: 34 start-page: 7862 year: 2014 end-page: 7870 ident: bb0195 article-title: Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults publication-title: J. Neurosci. – year: 2013 ident: bb0210 article-title: Cochrane handbook for systematic reviews of interventions version 5.1. 0. 2011 – volume: 54 start-page: 7 year: 2010 end-page: 16 ident: bb0290 article-title: Resveratrol bioavailability and toxicity in humans publication-title: Mol. Nutr. Food Res. – volume: 96 start-page: 1409 year: 2011 end-page: 1414 ident: bb0220 article-title: A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal publication-title: J. Clin. Endocrinol. Metab. – volume: 91 start-page: 1044 year: 2010 end-page: 1059 ident: bb0160 article-title: An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach publication-title: Am. J. Clin. Nutr. – volume: 32 start-page: 466 year: 2009 end-page: 471 ident: bb0230 article-title: Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis publication-title: Hypertens. Res. – volume: 6 start-page: 168 year: 2007 end-page: 173 ident: bb0100 article-title: Anti-inflammatory responses of resveratrol publication-title: Inflamm. Allergy Drug Targets – volume: 59 start-page: 330 year: 2009 end-page: 337 ident: bb0120 article-title: Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK publication-title: Pharmacol. Res. – volume: 21 start-page: R209 year: 2014 end-page: R225 ident: bb0085 article-title: Resveratrol and cancer: focus on in vivo evidence publication-title: Endocr. Relat. Cancer – volume: 5 start-page: 493 year: 2006 end-page: 506 ident: bb0005 article-title: Therapeutic potential of resveratrol: the in vivo evidence publication-title: Nat. Rev. Drug Discov. – volume: 85 start-page: 1288 year: 2013 end-page: 1296 ident: bb0110 article-title: SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging publication-title: Biochem. Pharmacol. – volume: 1–6 year: 2014 ident: bb0285 article-title: Pre-formulation studies of resveratrol publication-title: Drug Dev. Ind. Pharm. – volume: 95 start-page: 63 year: 2014 end-page: 71 ident: bb0050 article-title: Potential of resveratrol in the treatment of heart failure publication-title: Life Sci. – volume: 49 start-page: 472 year: 2005 end-page: 481 ident: bb0270 article-title: Metabolism and bioavailability of trans-resveratrol publication-title: Mol. Nutr. Food Res. – volume: 29 start-page: 178 year: 2013 end-page: 183 ident: bb0180 article-title: Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life publication-title: Nutrition – volume: 31 start-page: 842 year: 2011 end-page: 847 ident: bb0170 article-title: Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment publication-title: Nutr. Res. – volume: 110 start-page: 356 year: 2012 end-page: 363 ident: bb0190 article-title: One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease publication-title: Am. J. Cardiol. – volume: 58 start-page: 7 year: 2014 end-page: 21 ident: bb0300 article-title: Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans publication-title: Mol. Nutr. Food Res. – volume: 34 start-page: 7862 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0195 article-title: Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.0385-14.2014 – volume: 444 start-page: 566 year: 2006 ident: 10.1016/j.ijcard.2015.04.008_bb0295 article-title: Oenology: red wine procyanidins and vascular health publication-title: Nature doi: 10.1038/444566a – volume: 16 start-page: 658 year: 2012 ident: 10.1016/j.ijcard.2015.04.008_bb0205 article-title: Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance publication-title: Cell Metab. doi: 10.1016/j.cmet.2012.09.015 – start-page: 1 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0330 article-title: Preparation and in vitro/in vivo evaluation of resveratrol-loaded carboxymethyl chitosan nanoparticles publication-title: Drug Deliv. doi: 10.3109/10717544.2014.924167 – volume: 62 start-page: 1186 year: 2013 ident: 10.1016/j.ijcard.2015.04.008_bb0185 article-title: High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition publication-title: Diabetes doi: 10.2337/db12-0975 – volume: 19 start-page: 5384 year: 2013 ident: 10.1016/j.ijcard.2015.04.008_bb0090 article-title: Resveratrol and cancer treatment: is hormesis a yet unsolved matter? publication-title: Curr. Pharm. Des. doi: 10.2174/1381612811319300007 – volume: 34 start-page: 27 year: 2015 ident: 10.1016/j.ijcard.2015.04.008_bb0225 article-title: Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials publication-title: Clin. Nutr. doi: 10.1016/j.clnu.2014.03.009 – volume: 167 start-page: 205 year: 2015 ident: 10.1016/j.ijcard.2015.04.008_bb0325 article-title: Nutraceutical delivery systems: resveratrol encapsulation in grape seed oil nanoemulsions formed by spontaneous emulsification publication-title: Food Chem. doi: 10.1016/j.foodchem.2014.06.082 – volume: 31 start-page: 842 year: 2011 ident: 10.1016/j.ijcard.2015.04.008_bb0170 article-title: Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment publication-title: Nutr. Res. doi: 10.1016/j.nutres.2011.09.028 – volume: 10 start-page: 493 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0075 article-title: Resveratrol use in metabolic syndrome publication-title: Metab. Syndr. Relat. Disord. doi: 10.1089/met.2014.1505 – volume: 10 start-page: 1536 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0335 article-title: Resveratrol-loaded nanoparticles reduce oxidative stress induced by radiation or amyloid-beta in transgenic Caenorhabditis elegans publication-title: J. Biomed. Nanotechnol. doi: 10.1166/jbn.2014.1897 – year: 2005 ident: 10.1016/j.ijcard.2015.04.008_bb0145 – volume: 32 start-page: 1377 year: 2004 ident: 10.1016/j.ijcard.2015.04.008_bb0030 article-title: High absorption but very low bioavailability of oral resveratrol in humans publication-title: Drug Metab. Dispos. doi: 10.1124/dmd.104.000885 – volume: 49 start-page: 472 year: 2005 ident: 10.1016/j.ijcard.2015.04.008_bb0270 article-title: Metabolism and bioavailability of trans-resveratrol publication-title: Mol. Nutr. Food Res. doi: 10.1002/mnfr.200500010 – volume: 59 start-page: 330 year: 2009 ident: 10.1016/j.ijcard.2015.04.008_bb0120 article-title: Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2009.01.009 – volume: 5 start-page: 493 year: 2006 ident: 10.1016/j.ijcard.2015.04.008_bb0005 article-title: Therapeutic potential of resveratrol: the in vivo evidence publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd2060 – volume: 42 start-page: 12555 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0135 article-title: Resveratrol post-transcriptionally regulates pro-inflammatory gene expression via regulation of KSRP RNA binding activity publication-title: Nucleic Acids Res. doi: 10.1093/nar/gku1033 – volume: 335 start-page: 145 year: 2001 ident: 10.1016/j.ijcard.2015.04.008_bb0035 article-title: Absorption of trans-resveratrol in rats publication-title: Methods Enzymol. doi: 10.1016/S0076-6879(01)35239-4 – volume: 15 start-page: 14949 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0200 article-title: Pomegranate and its components as alternative treatment for prostate cancer publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms150914949 – volume: 54 start-page: 7 year: 2010 ident: 10.1016/j.ijcard.2015.04.008_bb0290 article-title: Resveratrol bioavailability and toxicity in humans publication-title: Mol. Nutr. Food Res. doi: 10.1002/mnfr.200900437 – volume: 85 start-page: 1288 year: 2013 ident: 10.1016/j.ijcard.2015.04.008_bb0110 article-title: SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2013.02.015 – volume: 20 start-page: 7366 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0055 article-title: Effects of resveratrol and other polyphenols in hepatic steatosis publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v20.i23.7366 – volume: 18 start-page: 864 year: 2005 ident: 10.1016/j.ijcard.2015.04.008_bb0235 article-title: Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats publication-title: Am. J. Hypertens. doi: 10.1016/j.amjhyper.2004.12.012 – volume: 62 start-page: 1784 year: 2010 ident: 10.1016/j.ijcard.2015.04.008_bb0245 article-title: Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats publication-title: J. Pharm. Pharmacol. doi: 10.1111/j.2042-7158.2010.01197.x – volume: 6 start-page: 168 year: 2007 ident: 10.1016/j.ijcard.2015.04.008_bb0100 article-title: Anti-inflammatory responses of resveratrol publication-title: Inflamm. Allergy Drug Targets doi: 10.2174/187152807781696464 – volume: 74 start-page: N17 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0080 article-title: Resveratrol and pharmacological potentiation in ischemic stroke publication-title: Neurosurgery doi: 10.1227/01.neu.0000450234.14363.07 – volume: 56 start-page: 455 year: 2000 ident: 10.1016/j.ijcard.2015.04.008_bb0155 article-title: Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis publication-title: Biometrics doi: 10.1111/j.0006-341X.2000.00455.x – ident: 10.1016/j.ijcard.2015.04.008_bb0210 – volume: 36 start-page: 79 year: 2003 ident: 10.1016/j.ijcard.2015.04.008_bb0040 article-title: Absorption of three wine-related polyphenols in three different matrices by healthy subjects publication-title: Clin. Biochem. doi: 10.1016/S0009-9120(02)00397-1 – volume: 17 start-page: 1975 year: 2003 ident: 10.1016/j.ijcard.2015.04.008_bb0025 article-title: Resveratrol: from grapevines to mammalian biology publication-title: FASEB J. doi: 10.1096/fj.03-0168rev – volume: 66 start-page: 799 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0065 article-title: Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies publication-title: Pharmacol. Rep. doi: 10.1016/j.pharep.2014.04.006 – volume: 58 start-page: 7 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0300 article-title: Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans publication-title: Mol. Nutr. Food Res. doi: 10.1002/mnfr.201200589 – volume: 54 start-page: 668 year: 2009 ident: 10.1016/j.ijcard.2015.04.008_bb0240 article-title: Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.109.133397 – year: 2015 ident: 10.1016/j.ijcard.2015.04.008_bb0265 article-title: Lipids, blood pressure and kidney update 2014 publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2015.03.009 – volume: 59 start-page: 865 year: 2000 ident: 10.1016/j.ijcard.2015.04.008_bb0105 article-title: Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production publication-title: Biochem. Pharmacol. doi: 10.1016/S0006-2952(99)00380-9 – volume: 51 start-page: 5867 year: 2003 ident: 10.1016/j.ijcard.2015.04.008_bb0015 article-title: Resveratrol in raw and baked blueberries and bilberries publication-title: J. Agric. Food Chem. doi: 10.1021/jf034150f – volume: 1–6 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0285 article-title: Pre-formulation studies of resveratrol publication-title: Drug Dev. Ind. Pharm. – volume: 120 start-page: 1123 year: 2010 ident: 10.1016/j.ijcard.2015.04.008_bb0320 article-title: Matrix effects on the bioavailability of resveratrol in humans publication-title: Food Chem. doi: 10.1016/j.foodchem.2009.11.032 – volume: 95 start-page: E1 year: 2010 ident: 10.1016/j.ijcard.2015.04.008_bb0215 article-title: An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2010-0482 – volume: 32 start-page: 466 year: 2009 ident: 10.1016/j.ijcard.2015.04.008_bb0230 article-title: Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis publication-title: Hypertens. Res. doi: 10.1038/hr.2009.47 – volume: 14 start-page: 806 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0095 article-title: From French paradox to cancer treatment: anti-cancer activities and mechanisms of resveratrol publication-title: Anti Cancer Agents Med. Chem. doi: 10.2174/1871520614666140521121722 – volume: 29 start-page: 178 year: 2013 ident: 10.1016/j.ijcard.2015.04.008_bb0180 article-title: Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life publication-title: Nutrition doi: 10.1016/j.nut.2012.07.006 – volume: 50 start-page: 3337 year: 2002 ident: 10.1016/j.ijcard.2015.04.008_bb0010 article-title: Plant foods and herbal sources of resveratrol publication-title: J. Agric. Food Chem. doi: 10.1021/jf0112973 – volume: 429 start-page: 273 year: 2010 ident: 10.1016/j.ijcard.2015.04.008_bb0280 article-title: Pleiotropic mechanisms facilitated by resveratrol and its metabolites publication-title: Biochem. J. doi: 10.1042/BJ20091857 – volume: 2014 start-page: 816307 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0070 article-title: Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients publication-title: ISRN Endocrinol. doi: 10.1155/2014/816307 – volume: 91 start-page: 1044 year: 2010 ident: 10.1016/j.ijcard.2015.04.008_bb0160 article-title: An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach publication-title: Am. J. Clin. Nutr. doi: 10.3945/ajcn.2009.28822 – volume: 34 start-page: 1109 year: 2007 ident: 10.1016/j.ijcard.2015.04.008_bb0130 article-title: Effects of resveratrol on number and activity of endothelial progenitor cells from human peripheral blood publication-title: Clin. Exp. Pharmacol. Physiol. doi: 10.1111/j.1440-1681.2007.04667.x – volume: 10 start-page: 524 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0275 article-title: Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells publication-title: Autophagy doi: 10.4161/auto.27593 – volume: 102 start-page: 1520 year: 2007 ident: 10.1016/j.ijcard.2015.04.008_bb0115 article-title: Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages publication-title: J. Appl. Physiol. doi: 10.1152/japplphysiol.00881.2006 – volume: 339 start-page: b2535 year: 2009 ident: 10.1016/j.ijcard.2015.04.008_bb0140 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: BMJ doi: 10.1136/bmj.b2535 – volume: 50 start-page: 179 year: 2012 ident: 10.1016/j.ijcard.2015.04.008_bb0175 article-title: Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease publication-title: Clin. Hemorheol. Microcirc. doi: 10.3233/CH-2011-1424 – volume: 1215 start-page: 9 year: 2011 ident: 10.1016/j.ijcard.2015.04.008_bb0305 article-title: Bioavailability of resveratrol publication-title: Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632.2010.05842.x – volume: 111 start-page: 1173 year: 2011 ident: 10.1016/j.ijcard.2015.04.008_bb0250 article-title: The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials publication-title: J. Am. Diet. Assoc. doi: 10.1016/j.jada.2011.05.015 – volume: 2014 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0165 article-title: Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients publication-title: Int. Sch. Res. Not. – volume: 110 start-page: 356 year: 2012 ident: 10.1016/j.ijcard.2015.04.008_bb0190 article-title: One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease publication-title: Am. J. Cardiol. doi: 10.1016/j.amjcard.2012.03.030 – volume: 30 start-page: 915 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0060 article-title: Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation publication-title: Nutrition doi: 10.1016/j.nut.2013.11.016 – volume: 32 start-page: 188 year: 2013 ident: 10.1016/j.ijcard.2015.04.008_bb0150 article-title: Does PPARgamma2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis publication-title: DNA Cell Biol. doi: 10.1089/dna.2012.1947 – volume: 96 start-page: 1409 year: 2011 ident: 10.1016/j.ijcard.2015.04.008_bb0220 article-title: A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2010-1812 – volume: 21 start-page: R209 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0085 article-title: Resveratrol and cancer: focus on in vivo evidence publication-title: Endocr. Relat. Cancer doi: 10.1530/ERC-13-0171 – volume: 30 start-page: 609 year: 2000 ident: 10.1016/j.ijcard.2015.04.008_bb0310 article-title: Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum publication-title: Xenobiotica doi: 10.1080/004982500406435 – volume: 339 start-page: 1523 year: 1992 ident: 10.1016/j.ijcard.2015.04.008_bb0020 article-title: Wine, alcohol, platelets, and the French paradox for coronary heart disease publication-title: Lancet doi: 10.1016/0140-6736(92)91277-F – volume: 171 start-page: 92 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0045 article-title: Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation publication-title: Br. J. Pharmacol. doi: 10.1111/bph.12409 – volume: 55 start-page: 1169 year: 2011 ident: 10.1016/j.ijcard.2015.04.008_bb0315 article-title: Enhancing the bioavailability of resveratrol by combining it with piperine publication-title: Mol. Nutr. Food Res. doi: 10.1002/mnfr.201100117 – volume: 95 start-page: 63 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0050 article-title: Potential of resveratrol in the treatment of heart failure publication-title: Life Sci. doi: 10.1016/j.lfs.2013.12.011 – volume: 205 start-page: 126 year: 2009 ident: 10.1016/j.ijcard.2015.04.008_bb0125 article-title: Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2008.11.011 – volume: 99 start-page: 1510 year: 2014 ident: 10.1016/j.ijcard.2015.04.008_bb0255 article-title: Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials publication-title: Am. J. Clin. Nutr. doi: 10.3945/ajcn.113.082024 – volume: 848 start-page: 182 year: 2007 ident: 10.1016/j.ijcard.2015.04.008_bb0260 article-title: Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography publication-title: J. Chromatogr. B Anal. Technol. Biomed. Life Sci. doi: 10.1016/j.jchromb.2006.10.017
SSID	ssj0004998
Score	2.5208728
SecondaryResourceType	review_article
Snippet	Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects on C-reactive protein... Abstract Introduction Numerous studies have suggested that oral supplementation with resveratrol exerts cardioprotective effects, but evidence of the effects...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	47
SubjectTerms	Antioxidants Antioxidants - administration & dosage C reactive protein C-Reactive Protein - drug effects C-Reactive Protein - metabolism Cardiotonic Agents Cardiovascular Cardiovascular Diseases - drug therapy Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control CRP Female Humans Inflammation Male Prognosis Randomized Controlled Trials as Topic Resveratrol Risk Assessment Severity of Illness Index Stilbenes - administration & dosage Survival Rate Treatment Outcome
Title	Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — Results from a systematic review and meta-analysis of randomized controlled trials
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0167527315007184 https://www.clinicalkey.es/playcontent/1-s2.0-S0167527315007184 https://www.ncbi.nlm.nih.gov/pubmed/25885871 https://www.proquest.com/docview/1683574731
Volume	189
WOSCitedRecordID	wos000355108300009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1874-1754 dateEnd: 20151215 omitProxy: false ssIdentifier: ssj0004998 issn: 0167-5273 databaseCode: AIEXJ dateStart: 19950106 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbWDSGEhLgNymUyEm8oU3NxYj9OVRGXUSFtQ32zHMfRUrp0Wtpp4okfwV_hD_FLOL6lLaUaIPESWW0cJzpffC75zjkIvSRRGRapZIFgpAySLCoCRpgImJQlKGxBhekN-OkwGw7paMQ-bnVu-1yYy0lW1_Tqip3_V1HDbyBsnTr7F-JuLwo_wBiEDkcQOxz_SPCHQhqyuNLFIXQzdxiDT32pqydrUjqIux-AqWg2ulemTkNlGcmN6YkDFqhcJaka-rlvzOPZEYmO_M8ns8ZmqIi1mtCWanymZiIQS5VPQDcW07Pqi17G0uQnMDTNQ5plS3k1VLlU4MLe3PLHgCNxqvLPlil-cFZdnILiV1WLetgOcxvm7Wu2YauHTrSvUc1N_Ff_0eonx1Iems8KjhLtAiMh0QQumxrqY6WgA3R9udXNni1t17bYp1P8tlzwmkqx0Y3xfjXWz6fJgMQUx-3RhQr1tIFB_30YNNF-LzjSq-vFweAGK862wfulsnfIm4j3-NqpHbQTZYTBHr1z8HYwerfI82Wmt3P7YD4V1PAV1-9vk6m1yZUyJtXxXXTH-UL4wGL4HtpS9X1084NjezxA3zWU8bTEHsp6vARlPK3xAsrYQRkDwLCHMl6FMtZQxg7K-MfXb9iBGGsQY4EXIMYWxOZqKyA2N9GCGC9AjC2IH6KT14Pj_pvAtRkJZELDWRDHSZnRVLeqLdMSlFhRkpTmSQmeTSQLFTIJTk4eZkLEJCYyjPMszZUSKs6YKGW8i7braa0eIyxCktOQFGXeE0kvT0VKWFlQwqRIVRrRLoq9RLh0Nfh1K5gJ92TLMbdy5FqOvJdwkGMXBe2sc1uD5prziRc29_nVYBFwQPQ187LfzVONe8cbvgmxXfTCY4qDetLfHEWtpnOYkYKLlyVwahc9smBrnyEilBKahU_-ed2n6NbizX-GtmcXc_Uc3ZCXs6q52EOdbET33Ev0E8_8HT0
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lack+of+efficacy+of+resveratrol+on+C-reactive+protein+and+selected+cardiovascular+risk+factors+%E2%80%94+Results+from+a+systematic+review+and+meta-analysis+of+randomized+controlled+trials&rft.jtitle=International+journal+of+cardiology&rft.au=Sahebkar%2C+Amirhossein&rft.au=Serban%2C+Corina&rft.au=Ursoniu%2C+Sorin&rft.au=Wong%2C+Nathan+D&rft.date=2015-06-15&rft.issn=0167-5273&rft.volume=189&rft.spage=47&rft.epage=55&rft_id=info:doi/10.1016%2Fj.ijcard.2015.04.008&rft.externalDBID=ECK1-s2.0-S0167527315007184&rft.externalDocID=1_s2_0_S0167527315007184
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01675273%2FS0167527315X0009X%2Fcov150h.gif